This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Effect of low dose, extended-release morphine on chronic breathlessness in chronic obstructive pulmonary disease (COPD)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Low-Dose, Extended-release Morphine on Chronic Breathlessness in Chronic Obstructive Pulmonary Disease (COPD)

  • randomized clinical trial including 156 people with COPD and chronic breathlessness, treatment with 8 mg/d and 16 mg/d of oral extended-release morphine for 1 week resulted in a mean difference of -0.3 and -0.3, respectively, for change in the intensity of worst breathlessness compared with placebo; neither difference was statistically significant
    • scores range from 0 to 10 (a score of 10 being the worst or most intense) on the numerical rating scale that was used
  • concludes:
    • extended-release morphine compared with placebo did not significantly reduce the intensity of worst breathlessness in people with COPD (1)
    • among people with COPD and severe chronic breathlessness, daily low-dose, extended-release morphine did not significantly reduce the intensity of worst breathlessness after 1 week of treatment

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.